Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

BACKGROUND: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. METHODS: Outcomes were evaluated for su...

Descripción completa

Detalles Bibliográficos
Autores principales: Powles, Thomas, Motzer, Robert J., Escudier, Bernard, Pal, Sumanta, Kollmannsberger, Christian, Pikiel, Joanna, Gurney, Howard, Rha, Sun Young, Park, Se Hoon, Geertsen, Poul F., Gross-Goupil, Marine, Grande, Enrique, Suarez, Cristina, Markby, David W., Arroyo, Alan, Dean, Mark, Choueiri, Toni K., George, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173766/
https://www.ncbi.nlm.nih.gov/pubmed/30197417
http://dx.doi.org/10.1038/s41416-018-0164-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173766/
https://www.ncbi.nlm.nih.gov/pubmed/30197417
http://dx.doi.org/10.1038/s41416-018-0164-0

Ejemplares similares